Tag: rivaroxaban
FDA approves two paediatric venous thromboembolism indications for Janssen’s Xarelto
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the US Food and Drug Administration (FDA) has approved two paediatric indications for...
Janssen submits new drug application to US FDA for Xarelto (rivaroxaban)...
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced it has submitted a new drug application (NDA) to the US Food and Drug...
Bayer receives approval in the UK for Xarelto to treat and...
Bayer has received approval in the UK for the use of its oral Factor Xa inhibitor Xarelto (rivaroxaban) to treat venous thromboembolism (VTE) and...
Rivaroxaban associated with reduced risk of recurrent VTE versus warfarin in...
In a study evaluating rivaroxaban (Xarelto; Bayer) versus warfarin for the treatment and prevention of recurrent venous thromboembolism (VTE) in patients with obesity, results...
Virtual ACC: Rivaroxaban demonstrates superiority over enoxaparin for prevention of VTE...
Results of PRONOMOS, a randomised, controlled, noninferiority trial, have shown rivaroxaban to be more effective than enoxaparin in the prevention of major venous thromboembolic...
Paediatric trial finds rivaroxaban similar to standard anticoagulation in treatment of...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing paediatric patients (aged birth to...
CASSINI trial results inconclusive on rivaroxaban effects in high-risk ambulatory cancer...
The CASSINI trial found that treatment with rivaroxaban did not significantly reduce the incidence of thromboembolism or death caused by thromboembolism in high-risk ambulatory...
Study proves need for anticoagulant strategy post discharge for hospitalised, at-risk...
Alex C Spyropoulos, from Feinstein Institute for Medical Research (New York, USA), has presented an anticoagulant treatment strategy to reduce non-fatal blood clots and...
Edoxaban emerges as alternative to dalteparin for cancer-associated VTE
A new analysis has identified patient populations with cancer-associated venous thromboembolism (VTE) who could benefit from treatment with oral anticoagulant edoxaban, taken once daily.
Daiichi...
FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...
Canadian study finds rivaroxaban more effective at preventing recurrent blood clots...
A Canadian-led international research team has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of...
Two new real-world studies confirm positive efficacy and safety profile of...
Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...